TY - JOUR T1 - Plasma Chromogranin A Levels Predict Survival and Tumor Response in Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors JF - Anticancer Research JO - Anticancer Res SP - 5661 LP - 5669 VL - 34 IS - 10 AU - WEN-CHI CHOU AU - JEN-SHI CHEN AU - YU-SHIN HUNG AU - JUN-TE HSU AU - TSE-CHING CHEN AU - CHIEN-FENG SUN AU - CHANG-HSIEN LU AU - TSANN-LONG HWANG Y1 - 2014/10/01 UR - http://ar.iiarjournals.org/content/34/10/5661.abstract N2 - Aim: To correlate the baseline and change of chromogranin A (CgA) levels with patient survival and tumor response in Asian patients with advanced gastro-enteropancreatic neuroendocrine tumors (GEP-NETs). Patients and Methods: Sixty patients with advanced GEP-NET treated in a medical center between April 2010 and April 2013 were enrolled retrospectively. Plasma CgA level was analyzed for correlation with the patient's clinical outcome and tumor response. Results: Multivariate analysis showed that independent favorable prognostic factors for overall survival were: Eastern Cooperative Oncology Groups performance score 0-1, World Health Organization tumor grade 1-2, single organ metastasis and less than twice the upper normal range of baseline CgA levels. Percentage changes in paired CgA tests (ΔCgA) of more than 17% can predict partial response or stable disease from progressive disease with 91.2% sensitivity and 82.9% specificity. Conclusion: Baseline plasma CgA levels predicted overall survival and ΔCgA predicted treatment response in Asian patients with GEP-NETs. ER -